The clinical relevance of this interrelation is underpinned by a study by Felsberg et al. who observed frequent decreases in MMR protein expression in recurrent GBM samples after TMZ treatment relative to their primary tumors [42]. This evidence concerns the gene MRC1 and glioblastoma.